EXEL

Exelixis Inc

64.53

Oct 23 • 3:59 PM ET -0.78 (-1.19%)

64.53

Aftermarket • 5:00 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Large NASD

Peers: INCY GMAB JAZZ ONC SMMT RVMD IBRX BMRN BMY NBIX

| Held by: IJH VTI VB XMHQ XBI VBK VXF MDY IBB FBT

Scroll to Statements

Index	-
Market Cap	15.99B
Enterprise Value	15.32B
Income	860.62M
Sales	2.44B
Book/sh	7.41
Cash/sh	3.39
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	1077
IPO	Apr 11, 2000

P/E	20.27
Forward P/E	15.38
PEG	0.80
P/S	6.56
P/B	8.71
P/C	19.05
P/FCF	13.64
EV/EBITDA	15.01
EV/Sales	6.29
Quick Ratio	3.38
Current Ratio	3.46
Debt/Eq	0.09
LT Debt/Eq	0.09
Option/Short	Yes / Yes

EPS (ttm)	3.18
EPS next Y	4.20
EPS next Q	0.89
EPS this Y	15.69%
EPS next Y	17.77%
EPS next 5Y	19.22%
EPS past 3/5Y	70.35% 51.19%
Sales past 3/5Y	12.93% 18.63%
EPS Y/Y TTM	53.08%
Sales Y/Y TTM	9.23%
EPS Q/Q	25.63%
Sales Q/Q	10.63%
Earnings	Oct 29 AMC
EPS/Sales Surpr.	6.63% -1.21%

Insider Own	3.22%
Insider Trans	-2.79%
Inst Own	105.80%
Inst Trans	-1.22%
ROA	33.28%
ROE	44.39%
ROIC	42.82%
Gross Margin	96.48%
Oper. Margin	40.72%
Profit Margin	35.33%
SMA20	6.39%
SMA50	11.19%
SMA200	28.14%
Trades

Shs Outstand	248.88M
Shs Float	239.80M
Short Float	11.75%
Short Ratio	11.94
Short Interest	28.18M
52W High	65.50 -1.48%
52W Low	36.00 79.25%
Volatility	1.98% 2.65%
ATR (14)	1.57
RSI (14)	70.68
Beta	0.48
Rel Volume	0.88
Avg Volume	2.36M
Volume	2,066,406

Perf Week	3.70%
Perf Month	11.35%
Perf Quarter	15.62%
Perf Half Y	43.59%
Perf YTD	47.23%
Perf Year	69.59%
Perf 3Y	235.22%
Perf 5Y	201.54%
Perf 10Y	458.22%
Recom	2.47
Target Price	55.50
Prev Close	65.31
Price	64.53
Change %	-1.19%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-19-26	Initiated	BMO Capital Markets	Market Perform	$54
Aug-06-26	Downgrade	Leerink Partners	Outperform → Market Perform	$52
Jun-25-26	Resumed	Truist	Hold	$54
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$48
Jan-05-26	Downgrade	BofA Securities	Neutral → Underperform	$41
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Nov-03-25	Downgrade	Guggenheim	Buy → Neutral
Oct-21-25	Upgrade	Leerink Partners	Market Perform → Outperform	$48
Sep-19-25	Resumed	Barclays	Equal Weight	$40
Sep-17-25	Resumed	Barclays	Equal Weight	$40
Sep-17-25	Initiated	Goldman	Buy	$47
Jul-08-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$45 → $50
Jun-24-25	Upgrade	Stephens	Equal-Weight → Overweight	$60
Feb-24-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$36
Jan-27-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$30 → $40
Jan-24-25	Downgrade	Oppenheimer	Outperform → Perform
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$36 → $40
Dec-17-24	Downgrade	BofA Securities	Buy → Neutral	$35 → $39
Oct-16-24	Reiterated	RBC Capital Mkts	Outperform	$30 → $34
Sep-19-24	Initiated	UBS	Neutral	$30

Show Previous Ratings

Today 08:23AM	Exelixis Rises with Earnings on Tap (FX Empire)
Oct-21-26 07:00PM	Exelixis Faces A Test Of Its Trimmed Outlook As Street Models Run Above Guidance (Earnings Whispers)
Oct-15-26 04:05PM	Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 (Business Wire)
Oct-14-26 04:07AM	Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda (PR Newswire)
Oct-12-26 01:54PM	GameStop Upgraded, Celestica Downgraded: Updated Rankings on Top Blue-Chip Stocks (InvestorPlace)
07:14PM	Loading…
Oct-07-26 07:14PM	Is Exelixis Stock Engineered To Make You Money? (Trefis)
Sep-30-26 03:43PM	Exelixis Shares Rising on CABOMETYX Revenue (FX Empire)
Sep-11-26 04:19PM	EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review William Blair Sees More Swings In Near Term (Stocktwits)
10:10AM	Exelixis, An IBD 50 Stock, Pulls A Bearish Move With Surprise Cancer Delay (Investor's Business Daily)
09:30AM	Exelixis Shares Fall 3.5% as FDA Extends Zanzalintinib Review by Three Months (InvestorsHub)
Sep-04-26 12:56PM	IBD Stock Of The Day Exelixis Hits Earnings Snag - And Then Breaks Out (Investor's Business Daily)
Sep-02-26 01:31PM	Cancer Stock Breaks Out To Highs; Key FDA Action On Watch (Investor's Business Daily)
Sep-01-26 04:05PM	Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September (Business Wire)
Aug-31-26 02:30PM	Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories (Business Wire)
Aug-28-26 11:23AM	Strong Sales, Earnings Send Exelixis Shares Higher (FX Empire)
02:36PM	Loading…
Aug-24-26 02:36PM	Exelixis Owners Keep Getting A Bigger Slice Of A Company In Transition (Trefis)
Aug-21-26 07:14PM	Exelixis, Valaris, and 3 More Stocks See Action From Activist Investors (Barrons.com)
Aug-06-26 04:14PM	Why This Top-Ranked IBD 50 Stock Just Tumbled On Its Earnings (Investor's Business Daily) -7.94%
01:04AM	Exelixis Inc (EXEL) (Q2 2026) Earnings Call Highlights: Strong Cabozantinib Growth Offsets NET ... (GuruFocus.com)
Aug-05-26 04:35PM	Exelixis: Q2 Earnings Snapshot (Associated Press)
04:05PM	Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update (Business Wire)
Jul-22-26 04:30PM	Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026 (Business Wire)
Jun-25-26 09:34AM	Qualcomm upgrade, Intel initiation among today's top calls on Wall Street (The Fly)
Jun-22-26 08:00AM	Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer (Business Wire)
Jun-10-26 08:25AM	Exelixis Hits High on Growing Sales, Institutional Inflows (FX Empire)
May-30-26 10:00AM	Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026 (Business Wire)
May-27-26 04:05PM	Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June (Business Wire)
May-21-26 05:00PM	Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types (Business Wire)
May-19-26 08:00AM	Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer (Business Wire)
May-07-26 04:05PM	Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May (Business Wire) -5.11%
04:13PM	Loading…
May-05-26 04:13PM	Exelixis: Q1 Earnings Snapshot (Associated Press) +9.64%
04:05PM	Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update (Business Wire)
Apr-21-26 04:05PM	Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026 (Business Wire) +5.23%
02:20PM	Why Dow Jones Stock Merck Skidded 4% - And Boosted A Key Rival (Investor's Business Daily)
Mar-30-26 07:52AM	Lillys AI commitment expands through deal with Insilico (BioPharma Dive)
Mar-02-26 09:40AM	Why Exelixis (EXEL) is a Top Value Stock for the Long-Term (Zacks) -6.88%
Feb-24-26 04:05PM	Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March (Business Wire)
10:58AM	Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge (PR Newswire)
09:50AM	Here's Why Exelixis (EXEL) is a Strong Momentum Stock (Zacks)
Feb-20-26 09:45AM	Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term (Zacks)
Feb-18-26 10:50AM	Expand Energy Q4 Earnings Call Highlights (MarketBeat)
Feb-16-26 09:15AM	A Dive into Exelixis (EXEL) International Revenue Trends and Forecasts (Zacks)
Feb-13-26 10:33AM	Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss (Zacks)
10:20AM	NVS Reports Positive Late-Stage Data on Kidney Disease Drug Vanrafia (Zacks)
09:40AM	Here's Why Exelixis (EXEL) is a Strong Value Stock (Zacks)
Feb-12-26 12:40PM	Exelixis Reports Solid Earnings-Are New Highs Back on the Table? (MarketBeat)
11:40AM	EXEL or LQDA: Which Is the Better Value Stock Right Now? (Zacks)
10:38AM	MDGL Strengthens MASH Franchise With New Genetic Approaches (Zacks)
10:30AM	Zoetis Stock Gains After Q4 Earnings & Revenues Beat Estimates (Zacks)
Feb-11-26 10:45AM	MRNA Down Nearly 10% as FDA Refuses to Review Influenza Vaccine BLA (Zacks)
09:56AM	EXEL Q4 Earnings and Revenues Beat, Colorectal Cancer Drug in Focus (Zacks)
12:01AM	Exelixis Inc (EXEL) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Feb-10-26 07:30PM	Compared to Estimates, Exelixis (EXEL) Q4 Earnings: A Look at Key Metrics (Zacks)
07:29PM	Exelixis Q4 Earnings Call Highlights (MarketBeat)
05:25PM	Exelixis (EXEL) Q4 Earnings and Revenues Beat Estimates (Zacks)
04:22PM	Exelixis: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update (Business Wire)
09:32AM	4 Discounted PEG Value Stocks to Boost Your Portfolio's Health (Zacks)
06:41AM	Why Exelixis (EXEL) is One of the Best Healthcare Stocks Under $50 to Invest In (Insider Monkey)
Feb-09-26 07:12PM	2 Intriguing Medical Stocks to Watch as Q4 Results Approach: EXEL, GILD (Zacks)
11:42AM	IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus (Zacks)
Feb-05-26 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL) (Zacks)
10:00AM	Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: Should You Buy? (Zacks)
Feb-04-26 09:45AM	Exelixis (EXEL) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
Feb-03-26 10:00AM	Exelixis (EXEL) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
09:50AM	Here's Why Exelixis (EXEL) is a Strong Momentum Stock (Zacks)
09:40AM	Should Value Investors Buy Exelixis (EXEL) Stock? (Zacks)
Feb-02-26 08:00AM	Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer (Business Wire)
Jan-31-26 07:13PM	2 Stocks That Could Soar This Year (Motley Fool)
Jan-28-26 05:42AM	Insilico and Qilu Pharmaceutical sign deal for cardiometabolic therapies (Pharmaceutical Technology)
Jan-27-26 04:05PM	Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026 (Business Wire)
11:40AM	EXEL vs. EXAS: Which Stock Is the Better Value Option? (Zacks)
09:40AM	Why Exelixis (EXEL) is a Top Value Stock for the Long-Term (Zacks)
Jan-20-26 04:59AM	Exelixis, Inc. (EXEL) Sees Mixed Analyst Actions as Zanzalintinib Nears Commercial Launch (Insider Monkey)
Jan-15-26 03:01PM	Exelixis, Inc. (EXEL): A Bull Case Theory (Insider Monkey)
09:50AM	Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term (Zacks)
Jan-14-26 12:10PM	Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Jan-12-26 09:33AM	Exelixis Posts Preliminary '25 Results, Issues '26 Outlook (Zacks)
Jan-11-26 04:00PM	Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026 (Business Wire)
Jan-09-26 05:18PM	Signet Jewelers, Natural Gas Services, and More Stocks See Action From Activist Investors (Barrons.com)
09:40AM	Here's Why Exelixis (EXEL) is a Strong Value Stock (Zacks)
Jan-08-26 08:50AM	EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study (Zacks)
05:35AM	2 Healthcare Stocks to Buy for 2026 and Beyond (Motley Fool)
Jan-07-26 08:00AM	Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer (Business Wire) +5.75%
Jan-06-26 04:05PM	Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026 (Business Wire)
Jan-03-26 07:20AM	Klaviyo, Wingstop among Stephens Best Ideas for 2026 (TipRanks)
Dec-31-25 12:46PM	See How Rare Bullish Inflows Lift Outliers Like Exelixis (FX Empire)
09:45AM	Here's Why Exelixis (EXEL) is a Strong Growth Stock (Zacks)
Dec-30-25 09:50AM	Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term (Zacks)
Dec-18-25 02:19PM	Exelixis Near A Buy Point. Relative Strength Rating Climbs. (Investor's Business Daily)
09:40AM	Why Exelixis (EXEL) is a Top Value Stock for the Long-Term (Zacks)
Dec-15-25 09:45AM	Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term (Zacks)
Dec-04-25 11:30AM	Why Is Exelixis (EXEL) Up 9% Since Last Earnings Report? (Zacks)
09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Dec-03-25 04:05PM	Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025 (Business Wire)
Dec-02-25 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Dec-01-25 08:06PM	2 Under-the-Radar Stocks to Buy Heading Into 2026 (Motley Fool)
Nov-28-25 09:45AM	Here's Why Exelixis (EXEL) is a Strong Growth Stock (Zacks)
Nov-17-25 09:15AM	Why Exelixis (EXEL) International Revenue Trends Deserve Your Attention (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Beckerle Mary C	Director	Aug 10 '26	Sale	53.66	9,812	526,512	16,079	Aug 12 07:34 PM
MARY BECKERLE	Director	Aug 10 '26	Proposed Sale	53.66	9,812	526,496		Aug 10 04:15 PM
WYSZOMIERSKI JACK L	Director	Jun 01 '26	Sale	50.55	3,925	198,409	284,384	Jun 03 06:52 PM
Eckhardt Sue Gail	Director	Jun 01 '26	Sale	50.14	9,812	491,974	16,079	Jun 03 06:51 PM
Eckhardt Sue Gail	Director	Jun 01 '26	Proposed Sale	50.87	9,812	499,136		Jun 01 04:16 PM
JACK L WYSZOMIERSKI	Director	Jun 01 '26	Proposed Sale	50.55	3,925	198,409		Jun 01 04:04 PM
Aftab Dana	EVP, Research and Development	May 26 '26	Sale	50.35	43,451	2,187,758	594,741	May 28 06:25 PM
DANA T AFTAB	Officer	May 26 '26	Proposed Sale	50.35	43,451	2,187,758		May 26 04:09 PM
Haley Patrick J.	EVP, Commercial	May 20 '26	Sale	49.81	32,110	1,599,399	357,638	May 22 05:01 PM
PATRICK JOSEPH HALEY	Officer	May 20 '26	Proposed Sale	49.81	32,110	1,599,444		May 20 04:31 PM
Senner Christopher J.	EVP and CFO	May 18 '26	Sale	50.00	34,901	1,745,050	952,317	May 19 06:58 PM
Hefti Brenda	SVP and General Counsel	May 18 '26	Sale	50.21	6,625	332,641	106,762	May 19 06:58 PM
CHRISTOPHER J SENNER	Officer	May 18 '26	Proposed Sale	50.00	34,901	1,745,179		May 18 04:49 PM
BRENDA JOY HEFTI	Officer	May 18 '26	Proposed Sale	50.21	6,625	332,641		May 18 04:23 PM
BOMBORA RISE FOUNDATION	Family foundation of the CEO o	May 14 '26	Proposed Sale	50.91	100,000	5,091,190		May 14 04:30 PM
Beckerle Mary C	Director	May 07 '26	Option Exercise	23.24	3,856	89,613	25,236	May 08 07:03 PM
Beckerle Mary C	Director	May 07 '26	Sale	48.45	7,712	373,646	17,524	May 08 07:03 PM
Freire Maria C	Director	May 07 '26	Option Exercise	19.77	20,634	407,934	121,453	May 08 07:03 PM
Freire Maria C	Director	May 07 '26	Sale	46.00	20,634	949,164	100,819	May 08 07:03 PM
POSTE GEORGE	Director	May 07 '26	Sale	45.71	60,000	2,742,600	118,832	May 08 07:03 PM
MARY BECKERLE	Director	May 07 '26	Proposed Sale	48.45	7,712	373,646		May 07 04:39 PM
GEORGE H POSTE	Director	May 07 '26	Proposed Sale	45.71	60,000	2,742,468		May 07 04:36 PM
MARIA C FREIRE	Director	May 07 '26	Proposed Sale	46.00	20,634	949,164		May 07 04:07 PM
Aftab Dana	EVP, Research and Development	Feb 24 '26	Sale	44.50	47,918	2,132,351	616,106	Feb 26 06:41 PM
DANA T AFTAB	Officer	Feb 24 '26	Proposed Sale	44.50	47,918	2,132,351		Feb 24 04:05 PM
Aftab Dana	EVP, Research and Development	Feb 19 '26	Sale	44.35	29,873	1,324,868	664,024	Feb 23 06:50 PM
WYSZOMIERSKI JACK L	Director	Feb 18 '26	Option Exercise	19.77	20,634	407,934	379,516	Feb 20 08:36 PM
WYSZOMIERSKI JACK L	Director	Feb 18 '26	Sale	44.01	99,574	4,382,252	279,942	Feb 20 08:36 PM
Smith Julie	Director	Feb 18 '26	Option Exercise	20.11	64,117	1,289,298	64,677	Feb 19 07:18 PM
Smith Julie	Director	Feb 17 '26	Option Exercise	18.19	42,422	771,656	63,012	Feb 19 07:18 PM
Smith Julie	Director	Feb 18 '26	Sale	44.44	64,117	2,849,200	20,590	Feb 19 07:18 PM
Smith Julie	Director	Feb 17 '26	Sale	43.33	42,422	1,838,145	20,590	Feb 19 07:18 PM
DANA T AFTAB	Officer	Feb 19 '26	Proposed Sale	44.35	29,873	1,324,868		Feb 19 04:06 PM
Senner Christopher J.	EVP and CFO	Feb 13 '26	Sale	43.00	34,278	1,473,954	1,042,579	Feb 18 08:49 PM
Senner Christopher J.	EVP and CFO	Feb 17 '26	Sale	43.67	30,617	1,337,044	976,092	Feb 18 08:49 PM
Haley Patrick J.	EVP, Commercial	Feb 17 '26	Sale	43.52	67,814	2,950,941	381,908	Feb 18 08:49 PM
MORRISSEY MICHAEL	President and CEO	Feb 13 '26	Option Exercise	21.31	494,700	10,542,057	2,319,941	Feb 18 08:49 PM
Eckhardt Sue Gail	Director	Feb 13 '26	Sale	43.79	3,856	168,854	17,524	Feb 18 08:49 PM
Oliver Bob	Director	Feb 13 '26	Option Exercise	19.28	9,088	175,217	51,370	Feb 18 08:48 PM
Oliver Bob	Director	Feb 13 '26	Sale	43.81	30,250	1,325,339	21,120	Feb 18 08:48 PM
Hefti Brenda	SVP and General Counsel	Feb 18 '26	Sale	44.01	18,669	821,623	96,512	Feb 18 08:48 PM
JULIE ANNE SMITH	Director	Feb 18 '26	Proposed Sale	44.44	64,117	2,849,200		Feb 18 05:55 PM
BRENDA JOY HEFTI	Officer	Feb 18 '26	Proposed Sale	44.01	18,669	821,664		Feb 18 04:30 PM
JACK L WYSZOMIERSKI	Director	Feb 18 '26	Proposed Sale	44.01	99,574	4,382,507		Feb 18 04:01 PM
JULIE ANNE SMITH	Director	Feb 17 '26	Proposed Sale	44.33	42,422	1,880,440		Feb 17 06:47 PM
CHRISTOPHER J SENNER	Officer	Feb 17 '26	Proposed Sale	43.67	30,617	1,337,035		Feb 17 06:45 PM
PATRICK JOSEPH HALEY	Officer	Feb 17 '26	Proposed Sale	43.52	67,814	2,951,083		Feb 17 06:43 PM
Eckhardt Sue Gail	Director	Feb 13 '26	Proposed Sale	42.89	3,856	165,384		Feb 13 04:39 PM
CHRISTOPHER J SENNER	Officer	Feb 13 '26	Proposed Sale	43.00	34,278	1,473,964		Feb 13 04:07 PM
ROBERT L OLIVER	Director	Feb 13 '26	Proposed Sale	43.82	30,250	1,325,408		Feb 13 04:07 PM
BOMBORA RISE FOUNDATION	Family foundation of the CEO o	Feb 12 '26	Proposed Sale	43.25	5,000	216,250		Feb 12 07:02 PM
Haley Patrick J.	Officer	Nov 20 '25	Proposed Sale	41.78	10,648	444,873		Dec 12 06:08 PM
JOHNSON DAVID EDWARD	Director	Nov 25 '25	Buy	43.12	27,532	1,187,235	1,553,262	Nov 26 04:05 PM
Haley Patrick J.	EVP, Commercial	Nov 20 '25	Sale	41.88	34,187	1,431,757	0	Nov 24 07:47 PM
Haley Patrick J.	EVP, Commercial	Nov 21 '25	Sale	42.58	28,043	1,194,071	374,029	Nov 24 07:47 PM
Haley Patrick J.	EVP, Commercial	Nov 20 '25	Sale	42.11	10,000	421,100	402,072	Nov 24 07:47 PM
PATRICK JOSEPH HALEY	Officer	Nov 20 '25	Proposed Sale	42.11	10,000	421,052		Nov 20 04:02 PM
PAPADOPOULOS STELIOS	Director	Nov 12 '25	Sale	43.55	100,000	4,355,000	1,189,228	Nov 13 07:12 PM
Aftab Dana	EVP, Research and Development	Nov 11 '25	Sale	42.50	48,383	2,056,278	664,778	Nov 13 07:12 PM
Beckerle Mary C	Director	Nov 11 '25	Option Exercise	23.24	5,784	134,420	46,002	Nov 13 07:12 PM
Beckerle Mary C	Director	Nov 11 '25	Sale	41.93	24,622	1,032,414	21,380	Nov 13 07:12 PM
JEFFREY J HESSEKIEL	Officer	Nov 13 '25	Proposed Sale	43.15	40,000	1,726,128		Nov 13 04:11 PM
Stelios Papadopoulos	Director	Nov 12 '25	Proposed Sale	43.55	100,000	4,355,204		Nov 12 05:41 PM
JEFFREY J HESSEKIEL	Officer	Nov 12 '25	Proposed Sale	43.02	60,000	2,581,006		Nov 12 04:16 PM
DANA T AFTAB	Officer	Nov 11 '25	Proposed Sale	42.50	48,383	2,056,360		Nov 12 10:30 AM
MARY BECKERLE	Director	Nov 11 '25	Proposed Sale	41.93	24,622	1,032,436		Nov 12 09:10 AM

Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Co-Founder & Independent Chair of the BoardDr. Stelios Papadopoulos Ph.D.

CEODr. Michael M. Morrissey Ph.D.

Executive VP & CFOMr. Christopher J. Senner

Ph.D.Dr. Brenda J. Hefti J.D.

Executive Vice President of Research & DevelopmentDr. Dana T. Aftab Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EXEL

Exelixis Inc

Upgrade your Finviz experience